Case ReportsIntravenous Valproic Acid Add-On Therapy in Acute Agitation Adolescents With Suspected Substance Abuse: A Report of Six CasesBattaglia, Claudia MD*; Averna, Roberto MD, PhD*; Labonia, Milena PsyD*; Riccioni, Assia MD†; Vicari, Stefano MD, PhD*Author Information *Department of Neuroscience, Child and Adolescence Neuropsychiatry Unit, Children Hospital Bambino Gesù and †Department of Neuroscience, Pediatric Neurology Unit, Tor Vergata University of Rome, Rome, Italy. Address correspondence and reprint requests to Claudia Battaglia, Department of Neurosciences and Neurorehabilitation, Bambino Gesù Children’s Hospital, P.zza Sant’Onofrio, 4, 00165 Rome, Italy; E-mail: firstname.lastname@example.org Conflicts of Interest and Sources of Funding: The authors have no conflicts of interest to declare. Clinical Neuropharmacology: 1/2 2018 - Volume 41 - Issue 1 - p 38-42 doi: 10.1097/WNF.0000000000000265 Buy Metrics Abstract The aim of this study was to test efficacy and safety of intravenous (IV) valproate for aggression in children and adolescents with mood or conduct disorder and concomitant substance abuse. Six patients received a 20 mg/kg dose of IV valproic acid as an add-on therapy to their standard therapy with second-generation antipsychotics and benzodiazepines. Agitation and general psychopathology were measured at baseline and after the first injection using the Modified Overt Aggression Scale, the Brief Psychiatric Rating Scale, and the Children’s Global Assessment Scale. The findings suggested that in emergency psychiatry clinical settings, IV valproate was effective in reducing agitation and aggressive behaviors with a good tolerability profile and better treatment compliance. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.